Brief: UCB Releases Bimekizumab New Three-Year Data In Hidradenitis Suppurativa At EADV

UCB SA

17/09/2025 06:22

Sept 17 (Reuters) - Ucb SA UCB.BR:

BIMEKIZUMAB NEW THREE-YEAR DATA IN HIDRADENITIS SUPPURATIVA AT EADV SHOWED SUSTAINED DISEASE CONTROL ACROSS MOST STRINGENT CLINICAL ENDPOINTS

IMPROVEMENTS IN STRINGENT ENDPOINTS HISCR75, HISCR90 AND HISCR100 AT ONE YEAR WERE SUSTAINED AND FURTHER IMPROVED TO THREE YEARS IN 81.2%, 64.3% AND 50.1% OF PATIENTS, RESPECTIVELY

OF PATIENTS WHO ACHIEVED IHS4-100 AT YEAR ONE, 64.3% ACHIEVED AND SUSTAINED THIS COMPLETE RESOLUTION OF INFLAMMATORY LESIONS THROUGH TO TWO YEARS

THREE-YEAR DATA FROM BE HEARD TRIALS FOR BIMZELX (BIMEKIZUMAB) IN MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Source text: [ID:]

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))